RxDoctor Payments Data

Stanley Ng, MD

Internal Medicine · New York, NYNPI 1760671317

Payments from drug & device makers

$23,426in general payments, 2019–2025

Across 187 payments — averaging $125.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$18K
  • Amarin Pharma, Inc.$908
  • Gilead$781
  • AstraZeneca$712
  • Esperion Therapeutics, Inc.$381
  • Medtronic$379
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$3,60015%
  • Speaking & faculty fees$10,26844%
  • Travel & lodging$4622%
  • Food & beverage$9,08339%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,426 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$24,245
Medicare patients
51
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl674$512,304
JanuviaSitagliptin Phosphate256$306,246
ProliaDenosumab137$237,567
FarxigaDapagliflozin Propanediol150$193,283
JardianceEmpagliflozin112$105,386
JanumetSitagliptin Phos/Metformin Hcl33$55,356
TradjentaLinagliptin53$54,282
EliquisApixaban71$52,503
LinzessLinaclotide39$32,432
Janumet XrSitagliptin Phos/Metformin Hcl18$26,582
VemlidyTenofovir Alafenamide15$21,063
XareltoRivaroxaban18$14,283
Icosapent Ethyl40$13,113
JentaduetoLinagliptin/Metformin Hcl17$12,968
Raloxifene Hcl318$10,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$22$388,184307 claims
AmgenProlia$18,473$237,567137 claims
AstraZenecaFarxiga$712$193,283150 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$165$172,636182 claims
PfizerEliquis$125$52,50371 claims
AbbVieLinzess$19$32,43239 claims
GileadVemlidy$781$21,06315 claims
Johnson & JohnsonXarelto$184$14,28318 claims
GSKShingrix$165$2,29216 claims
Lilly USA, LLCHumalog Mix 75-25$291$1,12613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →